Singapore markets close in 5 hours

Novavax, Inc. (NVAX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
141.55+6.56 (+4.86%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close134.99
Open150.75
Bid141.86 x 2900
Ask142.00 x 1200
Day's range140.23 - 156.32
52-week range76.59 - 331.68
Volume7,952,874
Avg. volume5,427,926
Market cap10.543B
Beta (5Y monthly)1.59
PE ratio (TTM)N/A
EPS (TTM)-13.84
Earnings date04 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est264.20
  • Editor's pick
    Yahoo Finance Video

    'The threat of COVID is not gone," says Milwaukee medical director

    Dr. Ben Weston, Milwaukee COVID-19 Emergency Operations Center Medical Director, talks about the process of approving the COVID-19 vaccine for children and the global fight against COVID-19.

  • Motley Fool

    Why Novavax Stock Is Jumping Today

    Shares of Novavax (NASDAQ: NVAX) were jumping 6.1% higher as of 10:48 a.m. EDT on Wednesday after rising as much as 15.8% earlier in the morning. The nice gain came following the company's announcement that it has filed for authorization of its COVID-19 vaccine NVX-CoV2373 to the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA). Novavax's U.K. submission is an important milestone for the company.

  • CNW Group

    Novavax Files for Authorization of its COVID-19 Vaccine in the United Kingdom

    Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the completion of its rolling regulatory submission to the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for authorization of its COVID-19 vaccine candidate. The company's application for Conditional Marketing Authorization (CMA) marks the first submission for authorization of a protein-based COVID-19 vaccine